BioCentury
ARTICLE | Clinical News

Altocor lovastatin XL: Phase II data; marketed to prevent coronary heart disease

September 30, 2002 7:00 AM UTC

In a placebo-controlled, double-blind Phase II trial in AD patients, 20-80 mg Altocor gave a 30%-44% reduction in low-density lipoprotein cholesterol (LDL-C), an 18%-31% reduction in total cholesterol...